Podcast Index
Parcourez les podcasts par catégorie, ouvrez les épisodes récents et téléchargez l’audio pour l’écouter hors ligne.
The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 Minutes
BZ Group
Hazel & Katniss & Harry & Starr
Brenna Clarke Gray and Joe Lipsett
The Dr. Laura Podcast
Dr. Laura Schlessinger & SiriusXM
Locked On 49ers - Daily Podcast On The San Francisco 49ers
Locked On Podcast Network, Brian Peacock
The World and Everything In It
WORLD Radio
10–12
LRT
NHKラジオニュース
NHK (Japan Broadcasting Corporation)
Locked On Raiders - Daily Podcast On The Las Vegas Raiders
Locked On Podcast Network, Your Boy Q
Rye Bread & Mustard: A Seattle Mariners Podcast
Myrone Sumner, Bleav
Kalenderblatt
Deutschlandfunk
The Dr. Laura Podcast
Dr. Laura Schlessinger & SiriusXM
Hunt. Fish. Freedom. - Presented By The International Order of T Roosevelt
International Order of T Roosevelt
Apolline Matin
RMC
besties
Lila & Werka
The Crowhouse
The Crowhouse
iHeartRadio 24/7 News: Weather
iHeartPodcasts and TTWN
Kā labāk dzīvot
Latvijas Radio 1
ハッピーイーティングラジオ
かなこ
Odd One Out - Daily Brain Teaser & Trivia Puzzle
Caloroga Labs
Entertainment & Celebrity News Today | 2 Min News | The Daily News Now!
The Daily News Now!
Slick’s open bar!
Tom Tiberi
A Morning Message To Start Your Day with Michael Allosso!
Michael Allosso
Frames of Fantasy
Frames of Fantasy
Viens! On parle...
Solène L
Cult of Conspiracy
The Cajun Knight & Raven Lee
5 Daily Trivia Questions – Can You Get All Five?
Caloroga Shark Media / 5 Daily Trivia Questions
Palace Intrigue : King Charles, Meghan Markle and all the Royal Family gossip
Caloroga Shark Media / The Daily Royal Family Podcast
Sports Card Nation Podcast
John Newman
River-Deep: A Riverdale Podcast
Emily & Abby
Daily Comedy News with Johnny Mac
Daily Comedy News with Johnny Mac
Dynasty Fantasy Football - Under The Helmet
Chad Parsons, Bleav
History Dispatches
Matt and McKinley Breen
Fun Facts Daily
Kyle Wood
The Good Morning Portugal! podcast with Carl Munson
Carl Munson
KIDSTORY : Les meilleurs contes pour enfants
Studio KODOMO
Renascença - Noticiários
Renascença
The Legal Podcast Network
The Legal Podcast Network (LPN)
Tout
BZ Group
J&J's Tecvayli–Talvey combo cut the risk of myeloma progression or death by 89% in earlier-line disease. Plus an FDA panel endorses wellness peptides including BPC-157, AstraZeneca's camizestran clears Europe in breast c...
GSK's Jideytro cleared the FDA two months early — a week after the $10.6B Nuvalent deal closed — for GSK's first lung cancer approval. Plus Arrowhead's plozasiran (Redemplo) posts best-case triglyceride and pancreatitis ...
Novo Nordisk sued Eli Lilly in federal court over "deceptive" ads comparing high-dose Zepbound and Mounjaro to lower-dose Wegovy and Ozempic. Also: Gilead and Merck back the first weekly oral HIV pill (islatravir/lenacap...
Tempus AI is buying Personalis for $1.5 billion, betting on cancer monitoring before reimbursement catches up. Plus Samsung Biologics' $1.8B all-cash bid for Swiss peptide maker PolyPeptide and its GLP-1 push, Legend Bio...
GSK wrote off most of a $2 billion bet as camlipixantbecomes the third P2X3 antagonist to fail in chronic cough. Plus Lilly's $2.8B AtaiBeckley deal and July's IPO wave, Novartis Fabhalta's full approval in IgAN, Celcuit...
GSK shelved camlipixant after mixed Phase 3 data — the third P2X3 chronic cough drug to fail and a blow to its ~$2B Bellus Health deal. Plus Jasper Therapeutics' lifeline merger with Kira and a $132M raise, Novartis Fabh...
Merck's sac-TMT beat chemotherapy in first-line PD-L1-negative lung cancer — the emerging answer to Keytruda's patent cliff. Plus: Europe approves Novo Nordisk's oral Wegovy ahead of Eli Lilly, Sanofi sues Pfizer and Mod...
Celcuity's Revtorpyk (gedatolisib) wins FDA approval in HR+/HER2- breast cancer on a 0.24 hazard ratio — and the stock jumped to $111. Plus AstraZeneca's up-to-$1.5B Zegfrovy license from spinoff Dizal, Biogen's diraners...
GSK will file Jemperli with the FDA for dMMR rectal cancer after a Phase 2 win, extending its PD-1 franchise into curative-intent oncology. Plus Q32 Bio's bempikibart hits its alopecia areata goal, the FDA finalizes psyc...
AstraZeneca's Wainua missed in cardiomyopathy — one of three clinical setbacks in five days even as pharma dealmaking stayed red-hot with Vertex's ~$10B Crinetics buy and GSK's biggest oncology bet in a decade. We break ...
GSK walked away from its $2.2 billion Alector alliance, ending its neuroscience re-entry as clinical setbacks piled up. Plus: the FDA resumes releasing rejection letters with fourteen new CRLs, Hengrui and Elevar's PD-1 ...
AstraZeneca and Ionis's Wainua missed its Phase 3 ATTR-CM endpoint — Ionis fell ~20% while BridgeBio surged ~17%. We break down the CARDIO-TTRansform failure and what it means for Alnylam's Amvuttra and BridgeBio's Attru...
The FDA quietly paused publishing complete response letters after a citizen petition — reversing the Makary-era transparency push and closing a live window into rival drug failures. Plus: Sino Biopharmaceutical's dual re...
Vera Therapeutics wins FDA accelerated approval for TRUTAKNA (atacicept) in IgA nephropathy on a 42% placebo-adjusted proteinuria cut — setting up a head-to-head with Otsuka's VOYXACT. Plus Oberland Capital's up-to-$400M...
Vertex pays $10B cash for Crinetics Pharmaceuticals — its largest deal ever — betting on acromegaly drug Palsonify and Phase 3 CAH candidate atumelnant. Also: Novartis acquires ADC platform Myricx Bio for up to $1.5B; HS...
Federal court blocks Colorado's 70% price cap on Enbrel — ruling could shut down state drug pricing laws nationwide. Plus: Casgevy label expansion to age 2 for SCD/TDT sends CRISPR Therapeutics surging 8%. Moderna mFLUSI...
Roche's divarasib beats both KRAS G12C rivals on PFS and OS in head-to-head Phase 3, hitting survival significance at interim. AstraZeneca returns to CSPC in a $1.7B siRNA kidney disease deal; Abivax surges on $920M rais...
FDA approves Orca Bio's Tregzi — the first precision-engineered cell therapy for allogeneic transplant, sparking IPO speculation. Plus BridgeBio secures $1B from Sixth Street and KKR at a 100%+ conversion premium, Ipsen'...
NEJM retracts Amgen's ADVOCATE study after FDA findsendpoint data for 9 patients re-evaluated post-unblinding. Plus: Ionis faces the Tryngolza sNDA PDUFA in severe hypertriglyceridemia, AbbVie's Epkinly delivers chemo-fr...
Lilly at $1,230 — trading above analyst consensus — as orforglipron faces its FDA verdict tomorrow. Three label items to watch beyond the headline, plus healthcare's dramatic sub-sector bifurcation: drug makers up 25% YT...
Remplissez le formulaire ci-dessous. Veillez à sélectionner à la fois Pays et Genres.
Envoyez-nous un message ci-dessous. Nous vous répondrons dans les 24 heures.